BAYRY vs TRVI: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BAYRY is the larger of the two ($57.45B market cap): the incumbent the market prices for continued execution (10.70x forward earnings, beta 0.81). TRVI is the smaller challenger ($1.92B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, TRVI fits (beta 1.12). If you want the steadier ride, BAYRY fits (beta 0.81).
BAYRY vs TRVI: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BAYRY | TRVI | What it tells you |
|---|---|---|---|
| Market cap | $57.45B | $1.92B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.70 | -22.14 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.81 | 1.12 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 35% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.75 | 6.33 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BAYRY and TRVI affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAYRY and TRVI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAYRY and TRVI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bayer AG (BAYRY) do?
Bayer AG is a Leverkusen-based life sciences company with three divisions. Crop Science (seeds, traits and crop protection, much of it inherited from the ~$63 billion Monsanto acquisition in 2018) is the largest by sales. Pharmaceuticals sells prescription drugs such as the anticoagulant Xarelto, the prostate cancer drug Nubeqa, the kidney and heart drug Kerendia, the eye drug Eylea outside the US, and the menopause treatment Lynkuet (elinzanetant). Consumer Health sells over-the-counter brands including Aspirin, Aleve, Claritin, Bepanthen and One A Day. Group sales were ~EUR 45.6 billion (~$51 billion) in 2025, and the primary listing is on Xetra in Frankfurt under BAYN, where it is a DAX member. BAYRY is a sponsored ADR that trades over the counter in the US, with four ADRs representing one ordinary share.
What does Trevi Therapeutics (TRVI) do?
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists that most rivals pursue. Trevi is targeting three indications: chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no marketed products and generates no product revenue, so it funds itself through equity raises and operates at a net loss, which is typical for a company at this stage.
BAYRY vs TRVI: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BAYRY drivers: Closing out the Roundup litigation; Crop Science margin recovery.
- TRVI drivers: Haduvio Phase 3 in IPF-related chronic cough; Refractory chronic cough expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework; about 65,000 claims were still pending in US courts as of the third-quarter report. For TRVI, trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value.
BAYRY or TRVI: which should you pick?
If the story you believe is BAYRY's (Closing out the Roundup litigation), BAYRY is the more direct way to own it; if it is TRVI's (Haduvio Phase 3 in IPF-related chronic cough), TRVI is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAYRY and TRVI guides.
BAYRY vs TRVI: the full fundamentals
BAYRY. At about $14.62 per ADR, Bayer trades at roughly 10.7 times forward earnings and around 8 times enterprise value to EBITDA on Yahoo data, a discount to large European pharma and agrochemical peers that reflects leverage and residual litigation risk. Reported net income is still negative over the trailing year (impairments and litigation charges), so trailing P/E figures on data sites look meaningless or distorted. The four analysts Yahoo tracks rate the ADR a buy with a mean target near $16.46, about 13% above the November 20 close.
TRVI. As a clinical-stage biotech, Trevi has no product revenue and runs at a net loss, so price-to-earnings does not apply. The roughly $1.9 billion market capitalization, about 6 times book value, reflects expectations for Haduvio's OCEAN and LAKE trials, with roughly $299 million of cash covering a meaningful slice of that value. Analysts expect a loss of about $0.49 per share for 2026 and $0.61 for 2027 as trials run; the average target of about $28 across 11 analysts sits well above the current price.
Headline figures (approximate, November 2026): BAYRY shows revenue (ttm) ~EUR 45.8 billion; Q3 2026 ~EUR 10.1 billion, q3 2026 ebitda before special items up ~7% year over year, ahead of consensus; full-year guidance raised, margins (ttm) ~59% gross, ~17% operating, ~-3% net, net income Q3 2026 net loss ~EUR 672 million; TTM ~-EUR 1.45 billion; TRVI shows market cap ~$1.9 billion, share price (nov 20, 2026) ~$13.53, cash and marketable securities (sept 30, 2026) ~$299 million, net loss (ttm) ~$61 million.
The bottom line: BAYRY vs TRVI
BAYRY and TRVI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BAYRY and TRVI exposure against your real portfolio. It is not an investment adviser.
Wondering how BAYRY or TRVI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Bayer AG
Ask Walnut's AI anything about BAYRY and see how it fits what you own.
FAQ
What is the difference between BAYRY and TRVI?
+
Bayer AG is a Leverkusen-based life sciences company with three divisions. Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BAYRY or TRVI the better stock?
+
Neither is universally better. BAYRY is the larger incumbent; TRVI is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BAYRY or TRVI?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BAYRY and TRVI?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BAYRY vs TRVI?
+
BAYRY: Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework; about 65,000 claims were still pending in US courts as of the third-quarter report. Impairments (about $341 million on Xofigo and $239 million on Claritin in the third quarter) show that special charges can keep pushing reported results into losses. Pharma faces continued generic erosion of Xarelto and Eylea, and pipeline setbacks (as with the earlier OCEANIC-AF failure of asundexian in atrial fibrillation) can reset expectations quickly. Crop Science is cyclical and exposed to farm economics, weather, trade policy and low-cost generic chemistry. Net financial debt near EUR 30 billion limits flexibility, and credit rating pressure would raise funding costs. For US holders of BAYRY there is also euro currency exposure, German dividend withholding tax, and thinner OTC trading than the Xetra listing. TRVI: Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter (the loss grew from about $13.2 million in Q1 2026 to $21.5 million in Q3) and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Timelines can slip, as the LAKE sample size re-estimation did when it moved from late 2026 into early 2027. Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Insiders have sold some stock (one September 2026 filing showed about $596,000 of sales), and the shares are down about 25% over three months to November 20, 2026, a reminder of how quickly sentiment can swing without new data. Finally, the ~$1.9 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BAYRY or TRVI; figures are approximate and dated (as of November 2026). Verify current data before investing.